XML 57 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]    
Schedule of stock option activity
  

Number of
Options

  

Weighted
Average
Exercise
Price

  

Weighted
Average
Remaining
Contractual
Life (Years)

  

Aggregate
Intrinsic
Value

 
Outstanding as of December 31, 2021   
—
                
Granted   4,347,492    5.15           
Exercised   
—
                
Cancelled/forfeited   
—
                
Outstanding as of March 31, 2022   4,347,492   $5.15    9.79   $498 

 

  

Number of
Options

  

Weighted
Average
Exercise
Price

  

Weighted
Average
Remaining
Contractual
Life (Years)

  

Aggregate
Intrinsic
Value

 
Outstanding as of December 31, 2021   31,962,921   $2.81    7.77   $86,075 
Granted   
—
                
Exercised   (268,702)   2.50         729 
Cancelled/forfeited   (1,049,835)   3.40           
Outstanding as of March 31, 2022   30,644,384   $2.79    7.34   $73,051 

 

  

Number of
Options

  

Weighted
Average
Exercise
Price

  

Weighted
Average
Remaining
Contractual
Life (Years)

  

Aggregate
Intrinsic
Value

 
Outstanding as of December 31, 2021   9,526,727   $5.55    8.0   $13,905 
Granted   
—
                
Exercised   (492,973)   2.41         1,037 
Cancelled/forfeited   (243,815)   8.02           
Outstanding as of March 31, 2022   8,789,939   $5.74    8.4   $10,759 

 

   Number of
Options
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding as of December 31, 2020   30,402,801   $2.45    8.75   $885 
Granted   5,287,031    4.74           
Exercised   (2,757,671)   2.30         7,740 
Expired/forfeited   (969,240)   3.65           
Outstanding as of December 31, 2021   31,962,921   $2.81    7.77   $86,075 
                     
Exercisable as of December 31, 2021   14,777,334   $2.51    6.93   $41,622 
Vested and expected to vest as of December 31, 2021   26,660,149   $2.73    7.59   $72,705 

 

   Number of
Options
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Life (Years)
   Aggregate
Intrinsic
Value
 
Outstanding as of December 31, 2020   6,490,208   $2.49    9.26   $1,174 
Granted   5,516,399    7.82           
Exercised   (1,630,925)   2.54         8,807 
Expired/Forfeited   (848,955)   2.68           
Outstanding as of December 31, 2021   9,526,727   $5.55    8.01   $13,905 
                     
Exercisable as of December 31, 2021   3,637,954   $2.95    6.24   $9,364 
Vested and expected to vest as of December 31, 2021   7,608,158   $4.81    7.68   $13,896 

 

Schedule of weighted-average assumptions
Risk-free interest rate:   1.61%
Expected term (in years):   7.01 
Expected volatility:   43.50%
Dividend yield:   0.00%

 

   2021   2020 
Risk-free interest rate:   0.79%   0.45%
Expected term (in years):   6.05    6.13 
Expected volatility:   42.10%   37.25%
Dividend yield:   0.00%   0.00%

 

   2021   2020 
Risk-free interest rate:   1.39%   0.59%
Expected term (in years):   9.06    10 
Expected volatility:   35.86%   38.42%
Dividend yield:   0.00%   0.00%

 

Schedule of stock-based compensation expense
   Three Months Ended
March 31,
 
   2022   2021 
Research and development  $1,622   $591 
Sales and marketing   374    199 
General and administrative   1,350    1,730 
   $3,347   $2,520 
   2021   2020 
Research and development  $4,001   $941 
Sales and marketing   1,185    387 
General and administrative   6,159    8,177 
   $11,345   $9,505 

 

Restricted stock awards for employee bonus, net  2021   2020 
Research and development  $7,613   $
—
 
Sales and marketing   2,310    
—
 
General and administrative   8,694    
—
 
   $18,617   $
—